ArticleJournal of inflammation research2026
Huazhuo Decoction Contributes to Immune Homeostasis and Attenuates Neuronal Inflammation and Demyelination in a Mouse Model of Multiple Sclerosis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS). Huazhuo decoction (HD) has been shown to ameliorate disease progression in MS patients, but the underlying mechanisms remain poorly understood. Purpose: This study sought to assess the therapeutic efficacy of HD in an experimental autoimmune encephalomyelitis (EAE) model of MS, and to further investigate the underlying mechanisms involved. Methods: We assessed the curative effects of HD on EAE mice via neurological function scoring and histological staining and identified the chemical composition of HD by UPLC-MS. RNA sequencing identified differentially expressed genes. Flow cytometry detected the proportions of splenic Th17, Th1, and Treg cells. Expression of key molecules was evaluated by Western blotting and quantitative PCR. Immunofluorescence was used to monitor microglia, astrocytes and oligodendrocytes. Results: HD alleviated neurobehavioral impairment, inflammatory infiltration and demyelination in EAE mice. RNA sequencing revealed that HD may ameliorate EAE by modulating adaptive immunity and affecting NLRP3-related signaling pathways. Further studies demonstrated that HD suppressed the upregulation of NF-κB/NLRP3 pathway, balanced the proportions of peripheral Th17, Th1 and Treg cells and regulated inflammatory cytokines. HD influenced innate immunity by reducing microglia and astrocytes and increasing oligodendrocytes in the CNS. Notably, these protective effects of HD were attenuated by an NLRP3 agonist. Conclusion: HD effectively alleviated the clinical symptoms of EAE mice and inhibited both peripheral and central immune inflammatory responses by modulating the NF-κB/NLRP3 pathway, providing a strong basis for its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.